Lyell Immunopharma, Inc. · NASDAQ:LYEL
ARCH Venture Fund IX, L.P. reported a 13.90% stake in Lyell Immunopharma, Inc. (Schedule 13G/A)
Event Mar 31, 2026 · Filed May 15, 2026
ARCH Venture Fund IX, L.P. reported a 13.90% stake in Lyell Immunopharma, Inc., 3,247,162 shares, as a passive investor on Mar 31, 2026. Filed May 15, 2026 (Schedule 13G/A).
- Stake
- 13.90%
- Shares
- 3,247,162
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 14 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| ARCH Venture Fund IX, L.P. | 13.90% | 3,247,162 |
| ARCH Venture Fund IX Overage, L.P. | 13.90% | 3,247,162 |
| ARCH Venture Fund XIII, L.P. | 13.90% | 3,247,162 |
| ARCH Venture Partners IX, L.P. | 13.90% | 3,247,162 |
| ARCH Venture Partners IX Overage, L.P. | 13.90% | 3,247,162 |
| ARCH Venture Partners IX, LLC | 13.90% | 3,247,162 |
| ARCH Venture Partners XIII, L.P. | 13.90% | 3,247,162 |
| ARCH Venture Partners XIII, LLC | 13.90% | 3,247,162 |
| Keith Crandell | 13.90% | 3,247,162 |
| Clinton Bybee | 7.80% | 1,820,634 |
| Robert Nelsen | 13.90% | 3,247,162 |
| Kristina Burow | 13.90% | 3,247,162 |
| Steven Gillis | 13.90% | 3,247,162 |
| Paul Berns | 6.10% | 1,426,528 |
Source
Related
- Lyell Immunopharma, Inc.
- Robert Nelsen
- Lyell Immunopharma, Inc. shareholders
- Schedule 13G/A · Robert Nelsen · Nov 14, 2025
- Form 4 · Aguirre Jarrad Mattieu · Oct 13, 2026
- Form 4 · Shook David · Sep 10, 2026
- Form 4 · Seely Lynn · Aug 25, 2026
- Form 4 · Hill Stephen J. · Aug 25, 2026
- Form 4 · Lee Gary K. · Aug 25, 2026